Tue, November 7, 2017
Mon, November 6, 2017
Fri, November 3, 2017
Thu, November 2, 2017
Wed, November 1, 2017
Tue, October 31, 2017
Mon, October 30, 2017
Fri, October 27, 2017

Gena Wang Maintained (BLUE) at Buy with Increased Target to $162 on, Nov 2nd, 2017

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-162-on-nov-2nd-2017.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

- Click to Lock Slider
Gena Wang of Barclays, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $151 to $162 on, Nov 2nd, 2017.

Gena has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Biren Amin of "Jefferies" Downgraded from Strong Buy to Hold on, Wednesday, October 11th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $109 on, Thursday, July 27th, 2017


These are the ratings of the 3 analyists that currently disagree with Gena


  • Matthew Luchini of "BMO Capital" Maintained at Buy with Increased Target to $162 on, Monday, October 30th, 2017
  • Josh Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy on, Monday, October 16th, 2017
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell on, Monday, October 2nd, 2017